Objective Platinum-based chemotherapy is the primary therapeutic intervention for over 500,000 patients per year in the EU. Although some patients are cured by this type of chemotherapy, as many as 75% of lung cancer patients and 60% of bladder cancer patients show no benefit and could be more appropriately given alternative treatments, and therefore over €4bn annually is wasted on unnecessary treatments. There is a need for a rapid, accurate test to distinguish those patients who are likely to respond to chemotherapy and those who are not. Accelerated Medical Diagnostics aim to personalise chemotherapy for cancer patients through their own developed PlatinDx assay, which can be used to identify those patients which are appropriate for platinum-based chemotherapy. Cancer patients are given a microdose (1% of the therapeutic dose) of a platinum-based drug, followed by quantitation of drug-DNA adducts in biopsy tissye using accelerator mass spectrometry (AMS). Levels of drug-DNA damage are measured by AMS in white blood cells and tumor biopsy tissue, which are used as a predictor of therapeutic response. Within the innovation project Accelerated Medical Diagnoistics intend to: gain medical certification within the EU; run a scaled up clinical trial to gain significant results; and adress the EU market and launch their service in the EU. Fields of science medical and health sciencesclinical medicineoncologybladder cancernatural scienceschemical sciencesanalytical chemistrymass spectrometry Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator ACCELERATED MEDICAL DIAGNOSTICS LTD Net EU contribution € 50 000,00 Address 72 Great Suffolk Street SE1 0BL London United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region London Inner London — East Lewisham and Southwark Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00 Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all HAMMERSMITH MEDICINES RESEARCH LTD United Kingdom Net EU contribution € 0,00 Address 44 CUMBERLAND AVENUE NW10 7EW London See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region London Outer London — West and North West Brent Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data
